Immunopotentiators	B-KP	0,18
activate	B-KP	19,27
innate	I-KP	28,34
immunity	I-KP	35,43
directly	O	44,52
(for	O	53,57
example,	O	58,65
cytokines)	O	67,77
or	O	78,80
through	O	81,88
pattern-recognition	B-KP	89,108
receptors	I-KP	109,118
(PRRs,	O	119,124
such	O	126,130
as	O	131,133
those	O	134,139
for	O	140,143
bacterial	O	144,153
components).	O	154,165

The	O	167,170
Toll-like	B-KP	171,180
receptors	I-KP	181,190
(TLRs)	O	191,197
are	O	198,201
a	O	202,203
family	O	204,210
of	O	211,213
PRRs	B-KP	214,218
that	O	219,223
are	O	224,227
an	O	228,230
important	O	231,240
link	O	241,245
between	O	246,253
innate	O	254,260
and	O	261,264
adaptive	O	265,273
immunity.	O	274,282

Some	O	284,288
studies	O	289,296
have	O	297,301
shown	O	302,307
that	O	308,312
TLR	B-KP	313,316
ligands	I-KP	317,324
have	O	325,329
adjuvant	O	330,338
activity	O	339,347
and	O	348,351
enhance	O	352,359
antigen-specific	O	360,376
antibody	O	377,385
and	O	386,389
cell-mediated	O	390,403
immune	O	404,410
responses,	O	411,420
especially	O	422,432
when	O	433,437
they	O	438,442
are	O	443,446
combined	O	447,455
with	O	456,460
delivery	O	461,469
systems	O	470,477
that	O	478,482
promote	O	483,490
their	O	491,496
uptake	O	497,503
and	O	504,507
delivery	O	508,516
into	O	517,521
antigen-presenting	B-KP	522,540
cells	I-KP	541,546
[22–24].	O	547,554

For	O	556,559
clinical	B-KP	560,568
studies,	I-KP	569,576
TLR9	B-KP	578,582
is	O	583,585
generally	O	586,595
stimulated	B-KP	596,606
with	O	607,611
synthetic	B-KP	612,621
oligodeoxynucleotides	I-KP	622,643
containing	O	644,654
one	O	655,658
or	O	659,661
more	O	662,666
unmethylated	B-KP	667,679
CpG	I-KP	680,683
dinucleotides.	I-KP	684,697

In	O	699,701
humans,	O	702,708
CpG	B-KP	710,713
has	O	714,717
been	O	718,722
used	O	723,727
as	O	728,730
an	O	731,733
adjuvant	B-KP	734,742
for	O	743,746
infectious	B-KP	747,757
disease	I-KP	758,765
vaccination	I-KP	766,777
[25,26]	O	778,785
and	O	786,789
in	O	790,792
the	O	793,796
development	I-KP	797,808
of	I-KP	809,811
cancer	I-KP	812,818
therapy	I-KP	819,826
[27].	O	827,831

In	O	833,835
a	O	836,837
mouse	B-KP	838,843
model,	I-KP	844,849
CpG	B-KP	851,854
has	O	855,858
also	O	859,863
been	O	864,868
shown	O	869,874
to	O	875,877
induce	B-KP	878,884
T	I-KP	885,886
helper	I-KP	887,893
1	I-KP	894,895
(Th1)	O	896,901
immune	O	902,908
responses,	O	909,918
which	O	920,925
are	O	926,929
characterized	O	930,943
by	O	944,946
the	O	947,950
production	B-KP	951,961
of	I-KP	962,964
IFN-γ	I-KP	965,970
and	I-KP	971,974
the	I-KP	975,978
generation	I-KP	979,989
of	I-KP	990,992
IgG2a	I-KP	993,998
[28,29].	O	999,1006

Moreover,	O	1008,1016
a	O	1018,1019
previous	O	1020,1028
study	O	1029,1034
had	O	1035,1038
demonstrated	O	1039,1051
that	O	1052,1056
different	O	1057,1066
liposomes	B-KP	1067,1076
with	O	1077,1081
CpG	O	1082,1085
ODN	O	1086,1089
significantly	O	1090,1103
increased	O	1104,1113
Th1-biased	B-KP	1114,1124
cytokines	I-KP	1125,1134
and	O	1135,1138
augmented	B-KP	1139,1148
cell	I-KP	1149,1153
mediated	I-KP	1154,1162
immune	I-KP	1163,1169
response	I-KP	1170,1178
[30].	O	1179,1183

